Modulating XIAP for the Treatment of Inflammatory Bowel Disease
调节 XIAP 治疗炎症性肠病
基本信息
- 批准号:10727185
- 负责人:
- 金额:$ 22.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:ART proteinAffectAgonistAllelesAnimal ModelAnti-Tumor Necrosis Factor TherapyApoptosisBackBindingCaspase InhibitorCell DeathCell Death InductionCell LineCellsCessation of lifeCharacteristicsChronicChronic DiseaseCicatrixClinicalColonCrohn&aposs diseaseCytoprotectionDNA DamageDataDiseaseDisease modelDown-RegulationEpigenetic ProcessEpithelial CellsExhibitsFoodFoundationsGastrointestinal tract structureGenesGeneticGoalsHematopoietic SystemHost DefenseHumanImpairmentIncidenceInduction of ApoptosisInflammasomeInflammationInflammatoryInflammatory Bowel DiseasesInjuryInterleukinsIntestinal CancerIntestinal DiseasesIntestinesKnockout MiceLeadMethylationMolecularMucous MembraneMusMutationNatural regenerationOrganOrganoidsOutputPatientsPhenotypePhysiologicalPrevalencePreventionProteinsRNA SplicingRelapseResistanceRiskRoleStressSystemTNF geneTP53 geneTestingTherapeuticTranscriptional ActivationTumor Suppressor ProteinsUbiquitinUlcerative ColitisUp-RegulationVariantWorkantagonistclinical developmentcommensal microbescytokinegastrointestinal systemgut inflammationhealinghigh throughput screeninginnate immune pathwaysintestinal epitheliummicrobiotamouse modelmulticatalytic endopeptidase complexmutantnovelnovel strategiespreventpro-apoptotic proteinpromoterprotein expressionprotein functionreduce symptomsresponsesmall moleculesymptom treatmenttherapeutic targettreatment strategytumorubiquitin-protein ligasex-linked inhibitor of apoptosis protein
项目摘要
PROPOSAL SUMMARY
Inflammatory bowel disease (IBD) is a highly prevalent intestinal disorder for which there is currently no cure.
The current treatment is comprised of anti-TNF therapy which alleviates the symptoms but does not target the
cause of the disease. Mutations in the X-linked Inhibitor of apoptosis protein (XIAP) have been identified in IBD
patients, suggesting that reduced XIAP activity causes IBD. One of the characteristic manifestations in IBD is
excessive death and damage to the intestinal epithelium, which contributes to intestinal inflammation because
of the compromised intestinal epithelial barrier against luminal microbiota. We propose to target the root cause
of IBD by directly restoring XIAP activity to homeostatic levels in patients with IBD. XIAP is the most potent
inhibitor of caspases and apoptosis. Reduced XIAP is associated with increased activation of the inflammasome
pathway of innate immune host defense and the upregulation of inflammatory tumor necrosis factor (TNF) and
interleukin (IL)-1b cytokines, resulting in hyperinflammation, which is also a characteristic of IBD. We predict
that regaining the normal activity of XIAP in IBD would control the excessive cell death of intestinal epithelial
cells and restore the healthy function and homeostatic turnover of the intestinal epithelium. The studies we
propose here will exploit the pro-apoptotic protein ARTS, which negatively regulates XIAP and promotes its
degradation by the Ubiquitin-Proteasome System. We hypothesize that ARTS serves as an important
therapeutic target for IBD by boosting the reduced activity of XIAP back to normal. Working with murine and
human colonic organoids, we will test the idea that reduced activity of XIAP in cells harboring IBD-associated
mutations can be overcome by inhibition of ARTS. Since expression of ARTS is induced in response to stress
and DNA-damage, this may also account for reduced XIAP activity in IBD patients without XIAP mutations. Thus,
strategies to raise XIAP activity may have broad impact beyond cases in which XIAP mutations are implicated
in IBD. Utilizing a complementary approach, we will modulate the activities of ARTS and XIAP using a proprietary
panel of small-molecule “ARTS-antagonists” and “XIAP-agonists” which we have identified. We seek to provide
proof-of-concept that our “ARTS-antagonists” and “XIAP-agonists” will be able to restore to normal the XIAP
function in cells with IBD-associated XIAP mutations as a novel treatment strategy for IBD. We will also test
these small molecules in an animal model of IBD. We have two specific aims: (1) Determine the role of ARTS
in regulating XIAP-induced apoptosis and inflammation in IBD, and (2) Identify the most potent ARTS-antagonist
and XIAP-agonist small molecules that restore XIAP expression and function in IBD models. Our proposal
provides a radical new approach for regulating XIAP by its natural antagonist ARTS, whose therapeutic
exploitation has not yet been investigated. Our long-term goal is the clinical development of compounds that
reverse damage to the intestinal epithelium and promote mucosal healing for an effective and long-lasting
treatment of IBD.
建议书摘要
炎症性肠病(IBD)是一种高度流行的肠道疾病,目前尚无治愈方法。
目前的治疗包括抗肿瘤坏死因子治疗,这种治疗可以缓解症状,但不针对
疾病的起因。已在IBD中发现X连锁的凋亡抑制蛋白(XIAP)突变
这表明XIAP活动减少导致IBD。炎症性肠病的特征之一是
过多的死亡和对肠道上皮的损害,这会导致肠道炎症,因为
对肠腔微生物群的肠道上皮屏障的破坏。我们建议针对根本原因
通过直接将IBD患者的XIAP活性恢复到动态平衡水平来治疗IBD。XIAP是最强大的
半胱氨酸氨基转移酶抑制物与细胞凋亡。XIAP降低与炎性小体的激活增加有关
天然免疫宿主防御途径与炎性肿瘤坏死因子和
白介素1b细胞因子,导致高度炎症,这也是IBD的特征。我们预测
IBD时XIAP恢复正常活性可控制肠上皮细胞过度死亡
从而恢复肠道上皮的健康功能和动态平衡。我们的研究
建议在这里利用促凋亡蛋白ARTS,它负向调节XIAP并促进其
泛素-蛋白酶体系统的降解。我们假设艺术是一种重要的
通过促进降低的XIAP活性恢复正常来治疗IBD。与小鼠和
人类结肠有机化合物,我们将测试在携带IBD相关疾病的细胞中XIAP活性降低的想法
基因突变可以通过抑制ARTS来克服。由于ARTS的表达是在应激反应中诱导的
和DNA损伤,这也可能是没有XIAP突变的IBD患者XIAP活性降低的原因。因此,
提高XIAP活性的策略可能会在涉及XIAP突变的病例之外产生广泛影响
在IBD。利用互补的方法,我们将使用专有的
我们已经确定的小分子“ARTS-拮抗剂”和“XIAP-激动剂”小组。我们寻求提供
证明我们的“艺术拮抗剂”和“XIAP激动剂”将能够使XIAP恢复正常
IBD相关XIAP突变细胞的功能作为治疗IBD的新策略。我们还将测试
这些小分子在IBD的动物模型中。我们有两个具体目标:(1)确定艺术的作用
在调节XIAP诱导的IBD细胞凋亡和炎症中的作用,以及(2)确定最有效的ARTS拮抗剂
以及在IBD模型中恢复XIAP表达和功能的XIAP激动剂小分子。我们的建议
为通过其天然拮抗剂ARTS调节XIAP提供了一种激进的新途径,其治疗作用
剥削还没有被调查。我们的长期目标是化合物的临床开发
逆转对肠上皮的损伤,促进粘膜愈合,有效而持久
IBD的治疗。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Julie Magarian Blander其他文献
Julie Magarian Blander的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Julie Magarian Blander', 18)}}的其他基金
Mobilizing TAP-independent CD8 T cells through non-canonical cross-presentation
通过非规范交叉呈递动员不依赖 TAP 的 CD8 T 细胞
- 批准号:
10659785 - 财政年份:2023
- 资助金额:
$ 22.55万 - 项目类别:
Toll-like receptor control of endocytic antigen cross-presentation
Toll 样受体控制内吞抗原交叉呈递
- 批准号:
10735354 - 财政年份:2023
- 资助金额:
$ 22.55万 - 项目类别:
Toll-like Receptor Control of MHC Class I Endocytosis
MHC I 类内吞作用的 Toll 样受体控制
- 批准号:
10557150 - 财政年份:2022
- 资助金额:
$ 22.55万 - 项目类别:
Toll-like Receptor Control of MHC Class I Endocytosis
MHC I 类内吞作用的 Toll 样受体控制
- 批准号:
10453097 - 财政年份:2022
- 资助金额:
$ 22.55万 - 项目类别:
Innate and Adaptive Immune Consequences of Necroptosis
坏死性凋亡的先天性和适应性免疫后果
- 批准号:
10196978 - 财政年份:2020
- 资助金额:
$ 22.55万 - 项目类别:
Innate and Adaptive Immune Consequences of Necroptosis
坏死性凋亡的先天性和适应性免疫后果
- 批准号:
10043494 - 财政年份:2020
- 资助金额:
$ 22.55万 - 项目类别:
Role of apoptosis in the intestinal epithelium during homeostasis and disease
肠上皮细胞凋亡在稳态和疾病过程中的作用
- 批准号:
9926879 - 财政年份:2017
- 资助金额:
$ 22.55万 - 项目类别:
Non-Canonical Cross-presentation in Dendritic Cells Upon TAP Blockade
TAP 阻断后树突状细胞中的非典型交叉呈递
- 批准号:
9404238 - 财政年份:2017
- 资助金额:
$ 22.55万 - 项目类别:
Novel vita-vaccine formula combines safety of dead and efficacy of live vaccines
新型维生素疫苗配方结合了死疫苗的安全性和活疫苗的功效
- 批准号:
9357501 - 财政年份:2016
- 资助金额:
$ 22.55万 - 项目类别:
Control of protective immunity by innate pathways sensing bacterial viability
通过感知细菌活力的先天途径控制保护性免疫
- 批准号:
8295078 - 财政年份:2012
- 资助金额:
$ 22.55万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 22.55万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 22.55万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 22.55万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 22.55万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 22.55万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 22.55万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 22.55万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 22.55万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 22.55万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 22.55万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




